CORDIS
EU research results

CORDIS

English EN
European Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools

European Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools

Objective

Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complimentary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialised in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mindset with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatical proficiency. Currently, there are no comprehensive training programmes to address this need. To move the promising liquid biopsy technology out of its infancy, the research programme and educational curriculum of the European Liquid Biopsy Academy (ELBA) will cover the entire value chain of diagnostics development and integrate all required disciplines and sectors.

ELBA will educate 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialisation of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. Most importantly, we have designed a well-balanced training programme to provide excellent career opportunities for the 15 ELBA ESRs. this includes training on state-of-the-art technologies and tools; bioinformatics, biostatistics and mathematical modelling; health economics and health technology assessment; diagnostic test development (including intellectual property and regulatory affairs); transferable skills (including leadership) and patient inclusion.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING VUMC

Address

De Boelelaan 1117
1081 Hv Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 510 748,56

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 498 432,96

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL

Spain

EU Contribution

€ 495 745,92

FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD

Portugal

EU Contribution

€ 476 712,72

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

France

EU Contribution

€ 525 751,20

PLOVDIVSKI UNIVERSITET PAISIY HILENDARSKI

Bulgaria

EU Contribution

€ 218 651,40

UNIVERSIDAD DE GRANADA

Spain

EU Contribution

€ 495 745,92

PANGAEA BIOTECH SL

Spain

EU Contribution

€ 247 872,96

EXOSOMICS SIENA SPA

Italy

EU Contribution

€ 258 061,32

Partners (12)

Sort alphabetically

Expand all

UNIVERSITEIT TWENTE

University Medical Centre, Utrecht

University of Padova

IZON SCIENCE LIMITED

GILUPI GMBH

TATAA BIOCENTER AB

GenomeScan B.V.

EUROPEAN CANCER PATIENT COALITION

Sense About Science

TTOPSTART BV

V.O. Patents & Trademarks

Factory-CRO BV

Project information

Grant agreement ID: 765492

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 727 722,96

  • EU contribution

    € 3 727 722,96

Coordinated by:

STICHTING VUMC

Netherlands